MedTrace Logo

National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns

NCT04664556 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2026-04-28

No results posted yet for this study

Summary

After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.

Conditions

  • Pneumococcal Infections
  • Pneumococcal Conjugate Vaccine
  • Antibiotic Treatment
  • Mortality

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Association Clinique Thérapeutique Infantile du val de Marne

    lead OTHER

Principal Investigators

  • Levy Corinne · Association Clinique Thérapeutique Infantile du val de Marne

  • Cohen Robert · Association Clinique Thérapeutique Infantile du val de Marne

Eligibility

Min Age
1 Day
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-13
Primary Completion
2030-01-01
Completion
2030-01-01

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04664556 on ClinicalTrials.gov